Laxido Apelsin (Sodium Hydrogen Carbonate, Potassium Chloride, Sodium Chloride, Macrogol 3350)

Laxido Apelsin, an osmotic laxative, is employed to manage conditions associated with reduced bowel motility.

• Constipation: softens stool and promotes regular bowel movements in patients with chronic or acute constipation.
• Occasional constipation: provides temporary relief of infrequent difficulty in passing stool without long‑term dependence.
• Bowel preparation: assists in cleansing the colon before diagnostic procedures such as colonoscopy or radiographic imaging.

• Macrogol 3350 is a high‑molecular‑weight polyethylene glycol that is minimally absorbed from the gastrointestinal tract. It creates an osmotic gradient that draws water into the intestinal lumen, increasing stool water content and volume. The added electrolytes—sodium hydrogen carbonate, potassium chloride and sodium chloride—help maintain electrolyte balance while the softened stool stimulates peristalsis, facilitating bowel evacuation. This mechanism results in a gentle, non‑stimulant laxation effect suitable for short‑term use.

Laxido Apelsin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Abdominal bloating: mild distension of the abdomen that usually resolves after continued use.
• Flatulence: increased intestinal gas leading to discomfort.
• Nausea: feeling of queasiness that may subside with ongoing therapy.
• Diarrhea: loose or watery stools occurring when the osmotic effect is pronounced.

Serious or Rare Side Effects

• Severe electrolyte imbalance: abnormal sodium or potassium levels that can affect cardiac function.
• Dehydration: excessive loss of body fluids leading to dizziness or low blood pressure.
• Allergic reaction: rash, itching, swelling, or difficulty breathing indicating hypersensitivity.

Before using Laxido Apelsin, consider the following precautions to ensure safe and effective use.

• Assess renal function: avoid use in severe renal impairment without medical supervision.
• Monitor electrolyte status: patients with existing electrolyte disorders should be evaluated before therapy.
• Use in children: dosage and duration should be determined by a pediatric clinician.
• Avoid prolonged use: limit to short‑term therapy unless advised by a healthcare professional.
• Pregnancy and lactation: consult a physician before use as safety data are limited.
• Store at ambient temperature: keep below 25°C, retain in original container, protect from moisture.

Laxido Apelsin can interact with certain medicines, affecting their absorption or electrolyte balance.

Major Interactions (Avoid)

• Digoxin: altered serum potassium may increase digoxin toxicity.
• Lithium: enhanced lithium reabsorption can raise serum levels, risking toxicity.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may reduce laxative efficacy.
• Oral antibiotics: accelerated intestinal transit can decrease antibiotic absorption.
• Diuretics: potential for additive electrolyte disturbances, especially potassium loss.